Nephrology · Medical Literature
T-Cell Engager–Mediated HLA Antibody Depletion before Kidney Transplantation
Abstract
New England Journal of Medicine, Volume 395, Issue 5, Page 511-513, July 30, 2026.
Clinical relevance
Can teclistamab, a bispecific BCMA×CD3 T-cell engager approved for multiple myeloma, deplete pathogenic HLA antibodies sufficiently in a highly sensitized kidney transplant candidate to enable successful deceased-donor kidney transplantation? __SNAPSHOT__ {"studyDesign":"Single-patient case report / proof-of-concept clinical observation (published as a correspondence letter in NEJM); not a controlled trial","setting":"Medical University of Vienna, Vienna, Austria; with collaborative analysis from University Hospital Basel (Switzerland) and University of Alberta (Canada)","sampleSize":"n=1 (single case)","population":"A 37-year-old dialysis-dependent male patient with high-level HLA sensitization developed following two prior kidney transplants, representing an extremely unfavorable immunological profile with essentially no realistic prospect of identifying a compatible deceased donor under standard allocation","intervention":"Teclistamab — a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager — administered over a 31-week treatment course prior to kidney transplantation, targeting and depleting antibody-producing plasma cells in blood and bone marrow","comparator":"Not applicable (single-arm, single-patient case report; no concurrent control)","primaryOutcome":"Reduction in anti-HLA antibody levels sufficient to reclassify previously unacceptable HLA donor antigens as acceptable, ultimately enabling deceased-donor kidney transplantation","followUp":"Not reported (post-transplant duration not specified in the abstract; institutional press release notes the patient has recovered well with excellent renal function)","fundingSource":"Not reported"}
Key findings
In a single highly sensitized patient who had failed conventional desensitization options, teclistamab administered over 31 weeks achieved a substantial and sustained reduction in anti-HLA antibody levels. Quantitative reductions in panel-reactive antibody scores, specific MFI values, or other serologic metrics are not reported in the available abstract. During the treatment course, HLA specificities that had previously been classified as unacceptable donor antigens were progressively reclassified as acceptable. This desensitization enabled identification of a compatible deceased-donor organ and successful kidney transplantation. Post-transplant, the patient was reported to have excellent allograft function and independence from dialysis. No formal adverse event data, safety analysis, or comparative efficacy statistics are reported in the abstract. NNT/NNH cannot be calculated from a single case report.
Practice implications
⚠ IMPORTANT LIMITATION: Only the abstract and institutional press release are available; the full text, supplementary appendix, detailed immunologic data, safety reporting, and post-transplant follow-up duration were not accessible for this summary. This is a single case report published as a correspondence letter in NEJM (3 journal pages), representing the lowest level of clinical evidence. It provides a clinically compelling proof-of-concept that BCMA-targeted T-cell engager therapy may deplete long-lived plasma cells responsible for sustained high-titer HLA alloantibody production — a mechanistic gap that has limited conventional desensitization strategies (plasmapheresis, IVIg, rituximab, bortezomib) for decades. The finding that an oncologic agent (teclistamab, FDA-approved for relapsed/refractory multiple myeloma) can achieve a level of HLA antibody clearance not previously attainable with transplant-specific desensitization protocols is scientifically novel and clinically significant as a hypothesis-generating observation. However, no conclusions about efficacy, optimal dosing, safety profile in non-oncologic patients, durability of response, or impact on transplant outcomes can be drawn from a single case. The patient population to whom these findings may apply — highly sensitized candidates (calculated PRA approaching 100%) who have failed or are ineligible for existing desensitization — is a real and underserved clinical group estimated to represent 20–30% of kidney transplant waitlist patients. The risks of teclistamab in a transplant context (infection, cytokine release syndrome, prolonged hypogammaglobulinemia, interference with post-transplant immunosuppression) require systematic study before clinical adoption. __LIMITATIONS__ Single case report (n=1): no internal comparator, no randomization, no control group; provides proof-of-concept only, not efficacy or safety evidence,Only abstract available; full immunologic data, safety data, dosing regimen details, concomitant medications, and post-transplant biopsy findings were not accessible for this summary,Publication format is a correspondence letter (3 pages), limiting the depth of methodological and outcomes reporting,No quantitative immunologic endpoints (e.g., specific MFI values, cPRA change, donor-specific antibody titers) are reported in the abstract,Post-transplant follow-up duration is not reported in the abstract; long-term allograft and patient outcomes are unknown,Teclistamab carries known oncologic risks (cytokine release syndrome, infections, hypogammaglobulinemia, neurotoxicity) whose incidence and severity in a non-myeloma transplant population are not characterized,The off-label use of an oncologic bispecific T-cell engager for desensitization has no established safety or dosing framework in transplant medicine,Generalizability is entirely uncertain from a single case; the degree of sensitization, prior treatments, HLA type, and donor characteristics unique to this patient may not be representative,Funding source and potential conflicts of interest are not reported in the abstract,Risk of outcome reporting bias inherent to single successful case publications ('publication bias toward success') __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ A single highly sensitized kidney transplant candidate received teclistamab (a BCMA×CD3 bispecific T-cell engager) for 31 weeks, achieving sufficient HLA antibody depletion to enable successful deceased-donor kidney transplantation — a first-in-kind proof-of-concept that plasma cell–directed immunotherapy may overcome the barrier of high-level allosensitization. This is a case report only; no efficacy, safety, or generalizability conclusions can be drawn, and routine clinical use is not supported at this time. Dedicated prospective trials are urgently needed to define the safety profile, optimal protocol, patient selection criteria, and transplant outcomes before this strategy is considered outside an experimental setting.